Artificial Intelligence

Former OpenAI Science Lead Launches Warp Sciences to Automate Wet Labs

Kevin Weil, a former OpenAI science lead, has officially launched Warp Sciences with a massive funding round to automate laboratory work using robots and human trainers.

Radwan AbdulhadiEditor and technology writer

Published: October 23, 2026 · Updated: October 23, 2026 · 4 min read

Former OpenAI Science Lead Launches Warp Sciences to Automate Wet Labs — Image: TechCrunch

Launch and Funding Overview

Former OpenAI science lead Kevin Weil has officially launched Warp Sciences, a new artificial intelligence startup designed to automate laboratory work dedicated to drug discovery. According to details shared by Weil on X, the newly unveiled company announced both its founding and a substantial $215 million funding round, securing an $865 million valuation in the process. The massive capital injection highlights strong investor enthusiasm for merging advanced robotics with biological research and automated laboratory environments.

The financing round was led by Lightspeed, with additional participation from several prominent institutional investors including IVP, Mayfield, Lux Capital, Premji Invest, and Menlo Ventures. This diverse syndicate of backers underscores the high stakes and broad industry interest in scaling up automated laboratory solutions to accelerate how pharmaceutical compounds are researched, synthesized, and rigorously tested.

Reshaping Drug Discovery and Supply Chains

For many years, biotechnology companies have largely outsourced the most labor-intensive tasks of synthesizing thousands of chemical variations and molecular combinations to third-party contractors based abroad, notably in China with firms such as WuXi AppTec. By introducing Warp Sciences, Kevin Weil aims to fundamentally reshore these critical operations back home. This strategic shift is intended to insulate the entire drug development pipeline from potential geopolitical supply chain disruptions and vulnerabilities.

The broader landscape of artificial intelligence in medicine has increasingly focused on addressing systemic labor shortages and bottlenecks. Industry observers frequently track developments across AI drug discovery, noting that innovations in automation and machine learning are gradually transforming how researchers approach complex biomedical challenges, rare diseases, and large-scale clinical pipelines.

Training Robots Through Human Expertise

To teach robotic systems how to operate effectively within complex laboratory settings, Warp Sciences employs a hands-on training methodology. Human chemists wear specialized sensor gloves and body-mounted cameras while performing everyday laboratory routines. These demonstrations capture precise physical movements, subtle techniques, and procedural nuances, allowing the startup to train robots to execute diverse lab tasks with high precision.

This human-in-the-loop demonstration model bridges the gap between traditional manual laboratory procedures and automated execution. By leveraging these recorded actions, the robotic systems learn to navigate dynamic wet-lab environments, handle delicate reagents, and manage standard equipment safely and reliably.

Accelerating Around-the-Clock Operations

By successfully automating wet-lab work, Warp Sciences seeks to drastically accelerate the pace of therapeutic research. Traditional laboratory procedures are frequently constrained by human shift schedules, manual bottlenecks, and the physical fatigue associated with repetitive tasks. In contrast, the startup's robotic workforce is designed to operate continuously around the clock.

Continuous operation enables researchers to synthesize and test promising compounds identified by advanced computational models at an unprecedented velocity. This capability aims to shorten the overall timelines required to move experimental drug candidates from initial conceptualization through to empirical validation.

Venture Capital Backing and Strategic Growth

The substantial financial backing led by Lightspeed provides Warp Sciences with the capital necessary to scale its engineering and biological operations rapidly. As the company deploys its newly acquired funds, it will focus on expanding its robotic infrastructure, refining its training mechanisms, and scaling up its physical facilities.

The intersection of advanced artificial intelligence, robotics, and biological engineering continues to attract significant venture capital investment. Startups operating in the robotics and biotech sectors are increasingly positioned to redefine traditional scientific workflows, offering scalable solutions to some of the most persistent operational hurdles in modern pharmaceutical research.